Marijuana-Derived Potential Therapeutics for Scleroderma

In this video by the Scleroderma Foundation, listen to Dr. Arnold Postlethwaite present about Marijuana-derived Potential Therapeutics for Scleroderma in 2014.

The body produces several cannabinoids (a class of biologically active compounds also found in cannabis sativa, or marijuana) that affect the function of cells in the brain and in most tissues of the body by binding to structures on cells called receptors.

These cannabinoids and receptors (called CB1 and CB2) make up the “endocannabinoid system.”

In this session, learn how the endocannabinoid system regulates blood vessel constriction and about functions of the immune system and fibrosis with particular relevance to systemic sclerosis.

The potential for drugs derived from non-psychoactive cannabinoids as therapeutics to treat pulmonary arterial hypertension, autoimmunity and fibrosis are discussed.

Learn more about scleroderma here: http://bit.ly/learnscleroderma